Event chart MERCK & CO., INC. |
|
|
Upcoming events on MERCK & CO., INC. |
|
05/24/22 | 09:00am | | Annual General Meeting |
07/28/22 | | Interim 2022 Earnings Release |
07/28/22 | 08:00am | | Interim 2022 Earnings Call |
10/27/22 | | Q3 2022 Earnings Release |
10/27/22 | 08:00am | | Q3 2022 Earnings Call |
02/02/23 | | FY 2022 Earnings Release (Projected) |
05/02/23 | | Q1 2023 Earnings Release (Projected) |
07/28/23 | | Interim 2023 Earnings Release (Projected) |
10/26/23 | | Q3 2023 Earnings Release (Projected) |
|
Past events on MERCK & CO., INC. |
|
05/11/22 | 11:40am | | Bank of America Healthcare Conference |
04/28/22 | 08:00am | | Q1 2022 Earnings Call |
04/28/22 | 06:30am | | Q1 2022 Earnings Release |
04/23/22 | | European clinical microbiology & infectious diseases congress - abstract number : 4545 |
04/23/22 | | European clinical microbiology & infectious diseases congress - abstract number : 4548 |
04/23/22 | | European clinical microbiology & infectious diseases congress - abstract number : 4514 |
04/23/22 | | European clinical microbiology & infectious diseases congress - abstract number : 4865 |
04/23/22 | | European clinical microbiology & infectious diseases congress - abstract number : 5113 |
04/05/22 | 10:00am | | Investor Meeting - Cardiovascular Event |
03/14/22 | | Ex-dividend day for |
|
Past dividends on MERCK & CO., INC. |
|
03/14/22 | | Quarterly 0.69 USD |
12/14/21 | | Quarterly 0.69 USD |
09/14/21 | | Quarterly 0.65 USD |
06/14/21 | | Quarterly 0.65 USD |
06/03/21 | | 0 |
03/12/21 | | Quarterly 0.65 USD |
12/14/20 | | Quarterly 0.65 USD |
09/14/20 | | Quarterly 0.61 USD |
06/12/20 | | Quarterly 0.61 USD |
03/13/20 | | Quarterly 0.61 USD |
|
|
Fiscal Period : December | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
Sales M $ |
Released Forecast Spread | 40 122 40 205 -0,21% | 42 294 42 234 0,14% | 46 840 46 818 0,05% | 47 994 48 177 -0,38% | 48 704 48 367 0,70% | 57 853 |
Operating income (EBITDA) M $ |
Released Forecast Spread | 15 131 15 472 -2,2% | 15 781 15 310 3,1% | 19 572 18 761 4,3% | 20 570 19 815 3,8% | 20 910 19 760 5,8% | 23 964 |
Operating profit (EBIT) M $ |
Released Forecast Spread | 13 551 13 722 -1,2% | 13 926 13 815 0,80% | 15 920 16 276 -2,2% | 16 945 17 366 -2,4% | 17 696 17 554 0,81% | 22 243 |
Pre-Tax Profit (EBT) M $ |
Released Forecast Spread | 6 747 6 720 0,40% | 8 701 8 296 4,9% | 11 464 12 277 -6,6% | 8 791 14 906 -41% | 13 879 12 048 15% | 19 102 |
Net income M $ |
Released Forecast Spread | 2 568 5 147 -50% | 6 220 6 462 -3,7% | 9 843 9 957 -1,1% | 7 067 12 094 -42% | 13 049 11 797 11% | 15 590 |
EPS $ |
Released Forecast Spread | 0,93 1,85 -50% | 2,32 2,44 -5,0% | 3,81 3,83 -0,52% | 2,78 4,71 -41% | 5,14 4,70 9,4% | 6,14 | Announcement Date | 02/02/2018 | 02/01/2019 | 02/05/2020 | 02/04/2021 | 02/03/2022 | - |
|
|
Fiscal Period : December | 2020 Q1 | 2020 Q2 | 2020 Q3 | 2020 Q4 | 2021 Q1 | 2021 Q2 | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 |
Sales M $ |
Released Forecast Spread | 12 057 11 458 5,2% | 10 872 10 657 2,0% | 12 551 12 213 2,8% | 12 514 12 668 -1,2% | 12 080 12 648 -4,5% | 11 402 11 193 1,9% | 13 154 12 320 6,8% | 13 521 13 212 2,3% | 15 901 14 648 8,6% | 13 648 | 14 190 | 13 842 | 13 800 | 13 900 |
Operating income (EBITDA) M $ |
Released Forecast Spread | 4 802 4 715 1,8% | 4 707 3 911 20% | 5 744 4 862 18% | 4 608 4 606 0,04% | 5 220 5 416 -3,6% | 4 659 4 555 2,3% | 6 111 5 175 18% | 5 670 4 892 16% | 5 918 | 4 960 | 5 937 | 5 206 |
|
|
Operating profit (EBIT) M $ |
Released Forecast Spread | 3 981 4 205 -5,3% | 3 659 3 238 13% | 4 892 4 342 13% | 3 704 4 047 -8,5% | 4 290 4 844 -11% | 3 969 4 032 -1,6% | 5 352 4 708 14% | 4 835 4 528 6,8% | 6 448 5 393 20% | 4 932 | 5 594 | 4 862 |
|
|
Pre-Tax Profit (EBT) M $ |
Released Forecast Spread |
|
|
|
|
| 1 717 3 367 -49% |
|
|
|
|
|
|
|
|
Net income M $ |
Released Forecast Spread | 3 219 2 856 13% | 3 002 2 323 29% | 2 941 2 575 14% | -2 094 2 773 -176% | 3 179 3 712 -14% | 1 214 2 805 -57% | 4 567 3 078 48% | 3 758 3 557 5,6% | 4 310 3 768 14% | 3 512 | 3 660 | 3 385 |
|
|
EPS $ |
Released Forecast Spread | 1,26 1,12 13% | 1,18 0,91 29% | 1,16 1,02 14% | -0,83 1,05 -179% | 1,25 1,43 -13% | 0,48 0,82 -41% | 1,80 1,35 33% | 1,48 1,35 9,8% | 1,70 1,48 15% | 1,39 | 1,49 | 1,31 |
|
| Announcement Date | 04/28/2020 | 07/31/2020 | 10/27/2020 | 02/04/2021 | 04/29/2021 | 07/29/2021 | 10/28/2021 | 02/03/2022 | 04/28/2022 | - | - | - | - | - | |
|
|
Upcoming sector events for MERCK & CO., INC. |
|
|
|
Past sector events for MERCK & CO., INC. |
|
|
|
|
|
|
Merck sees up to $7 billion in sales of COVID-19 drug through end of 2022 |
|
MERCK AND COMPANY Leader in oncology, modest valuation |
Net sales (Year) - Rate of surprise
EPS (Year) - Rate of surprise
Net sales (Quarter) - Rate of surprise
EPS (Quarter) - Rate of surprise
|